An observational study of *Pseudomonas aeruginosa* in adult long-term ventilation

Ruth Sobala 1, Hannah Carlin1, Thomas Fretwell1, Sufyan Shakir1, Katie Cattermole1, Amy Royston 1, Paul McCallion 2, John Davison2, Joanna Lumb2, Hilary Tedd1, Ben Messer1,4 and Anthony De Soyza1,2,3,4

1North East Assisted Ventilation Service, Newcastle Upon Tyne Hospitals Trust, Newcastle, UK. 2Freeman Hospital, Newcastle, UK. 3Population Health Science Institutes, Newcastle University, Newcastle, UK. 4These authors contributed equally.

Corresponding author: Ruth Sobala (Ruth.sobala1@nhs.net)

Shareable abstract (@ERSpublications)

*Pseudomonas aeruginosa* isolation is common (17%) in long-term ventilated adults and significantly associated with tracheostomy, cystic fibrosis and bronchiectasis. Tracheostomy patients with *P. aeruginosa* isolates culture copathogens more frequently. https://bit.ly/3vvxBbB

Cite this article as: Sobala R, Carlin H, Fretwell T, et al. An observational study of *Pseudomonas aeruginosa* in adult long-term ventilation. *ERJ Open Res* 2022; 8: 00687-2021 [DOI: 10.1183/23120541.00687-2021].

Abstract

**Introduction** *Pseudomonas aeruginosa* increases morbidity and mortality in respiratory disease. To date the long-term ventilation population does not have clear guidelines regarding its management.

**Method** We undertook a retrospective observational study in a regional long-term ventilation population (837 patients). We defined the primary outcome as *P. aeruginosa* isolation. In addition positive cultures for copathogens (*Serratia*, *Proteus* species, *Stenotrophomonas*, *Burkholderia cepacia* complex and nontuberculous mycobacteria) were recorded. Logistic regression and odds ratios were calculated.

**Results** 17.6% of the cohort isolated *P. aeruginosa*, and this pathogen was cultured more frequently in patients with a tracheostomy (logistic regression coefficient 2.90, p ≤ 0.0001) and cystic fibrosis/bronchiectasis (logistic regression coefficient 2.48, p ≤ 0.0001). 6.3% of patients were ventilated via tracheostomy. In the *P. aeruginosa* positive cohort 46.9% of patients were treated with a long-term macrolide, 36.7% received a nebulised antibiotic and 21.1% received both. Tracheostomised *P. aeruginosa* positive patients received a nebulised antibiotic more frequently (OR 2.63, 95% CI 1.23–5.64, p=0.013). Copathogens were isolated in 33.3% of the *P. aeruginosa* cohort. In this cohort patients with a tracheostomy grew a copathogen more frequently than those without (OR 2.75, 95% CI 1.28–5.90).

**Conclusions** *P. aeruginosa* isolation is common within the adult long-term ventilation population and is significantly associated with tracheostomy, cystic fibrosis and bronchiectasis. Further research and international guidelines are needed to establish the prognostic impact of *P. aeruginosa* and to guide on antimicrobial management. The increased risk of *P. aeruginosa* should be considered when contemplating long-term ventilation via tracheostomy.

**Introduction** *Pseudomonas aeruginosa* (*Pa*) is a well-recognised opportunistic Gram-negative respiratory pathogen affecting a number of patient groups with underlying respiratory diseases. These include patients with COPD, bronchiectasis and cystic fibrosis (CF). It drives both morbidity [1] and early mortality [2] in the latter two diseases leading to guideline recommendations to conduct surveillance for detecting this pathogen [3, 4]. Additionally guidelines recommend the use of either systemic (e.g. long-term macrolides) or pulmonary-targeted antibiotic therapies (e.g. nebulised antibiotics) to reduce exacerbation rates [3, 4].

Home long-term ventilation (LTV) services have a diverse range of aetiologies under their care. Common indications include congenital muscular dystrophies such as Duchenne muscular dystrophy (DMD), acquired neuromuscular disorders such as motor neurone disease (MND), restrictive chest wall conditions such as kyphoscoliosis, diaphragm palsy, sleep disordered breathing, obesity hypoventilation syndrome (OHS) and respiratory diseases such as those documented above.
In acute illness, when invasive ventilation is required, there is an increased risk of *P. aeruginosa* infection, *i.e.* ventilator-associated pneumonia, and data for patients chronically invasively ventilated in a home care setting suggest *P. aeruginosa* is common within a year of discharge [5].

Improving survival rates on LTV (both invasive and noninvasive), has resulted in increasingly complex patients being managed by LTV services. These patients are managed by specialist centres. However, there is minimal literature on the burden of *P. aeruginosa* in those requiring home LTV. In the absence of guidelines on managing this infection outside of CF and bronchiectasis [3, 4] we sought to describe both the prevalence of *P. aeruginosa* in our home ventilation cohort and the management strategies applied.

**Material and methods**

**Study population**

We undertook a retrospective observational study on a regional LTV population. The service covers the North East and Cumbria, with a population of 3 million. It is the primary care provider for LTV patients in the region and receives referrals from 11 hospitals. Three satellite clinics are required.

The population of patients was identified using the regional LTV database. At the time of access (March 2021) the database consisted of 837 active adult patients. LTV care was defined as receiving noninvasive ventilation (NIV), mechanical insufflation–exsufflation (MI-E), both treatments or high-flow nasal cannula. The database contained the indication for LTV.

**Data collection**

Electronic medical records at our hospital and referring units were accessed to record the additional information: *P. aeruginosa* cultured ever, *P. aeruginosa* cultured in the last 2 years, *P. aeruginosa* treated with a nebulised antibiotic or a long-term macrolide, presence of tracheostomy for ventilation, requirement for long-term oxygen therapy (LTOT) or ambulatory oxygen therapy (AOT), and prescription of the mucolytic carbocisteine.

Patients were grouped according to individual diagnosis or categories as follows: airway disease (asthma/COPD), CF/bronchiectasis, interstitial lung diseases, restrictive chest wall conditions, diaphragm palsy, OHS and obstructive sleep apnoea (OSA), MND, DMD, all other neuromuscular disease (*e.g.* myopathies and dystrophies), cerebral palsy, spinal cord injury, other neurological conditions and other (*i.e.* miscellaneous) (see supplementary appendix 1). Patients with COPD–OSA overlap were included within the airway disease category.

We defined the primary outcome as *P. aeruginosa* colonisation, identified through historical or current respiratory culture results. In view of the common inherent resistance of certain bacterial species to colistin (colistimethate sodium) we also recorded any present or historically positive cultures for *Serratia*, *Proteus* species, *Stenotrophomonas*, *Burkholderia cepacia* complex and nontuberculous mycobacteria (NTM).

**Data analysis**

We described observed frequencies and compared distributions using odds ratios. A logistic regression was performed (Mathematica, Version 12.3.1; Wolfram Research Inc., Champaign, IL, USA (2021)) to determine the independent effects of disease type and the presence/absence of tracheostomy on *P. aeruginosa* isolates.

**Results**

We identified 837 patients under the regional LTV service and accessed present and historical microbiology results for all of them. 6.3% were ventilated *via* tracheostomy. 17.6% were culture positive for *P. aeruginosa* (from airway samples: sputum, tracheal aspirates, bronchial lavage) and 8.6% culture positive within the last 24 months. Within the *P. aeruginosa* positive cohort the mean age was 52 years with male:female ratio 1.88:1, reflecting the male dominant disease pattern of several LTV conditions. At time of data gathering (March 2021) patients had received ventilation for a mean of 1828 days (5 years). 36.1% of *P. aeruginosa* positive patients were on both LTV and MI-E, 18.4% solely on MI-E and 6.8% used a lung volume recruitment bag in addition to LTV. Two patients received ventilation *via* high-flow nasal cannula.

Patients with CF and patients with tracheostomy had the highest prevalence of *P. aeruginosa* colonisation (74.2% and 71.7% respectively). Spinal cord injury and the grouping “other” (*e.g.* ventilatory failure of unknown origin, global developmental delay, *etc.*) had the highest numbers of tracheostomy patients. Patients with primary respiratory diseases (COPD, asthma, bronchiectasis, CF) did not require tracheostomy. 33.3% of patients using an MI-E device had positive *P. aeruginosa* isolates.
Demographic and clinical data are described in table 1, including the prevalence of Pa by diagnostic subgroup, and by tracheostomy. The prevalence of Pa in patients with CF/bronchiectasis was high, as expected (74.2%); however, there was also a high burden of disease in patients with spinal cord injuries (40.0%), other (33.3%), cerebral palsy (31.6%) and DMD (26.9%).

Logistic regression (LR) was performed to account for the confounding variables created by tracheostomy and disease group (see table 2). This identified tracheostomy as being the strongest positive factor associated with Pa (LR coefficient 2.90, p≤0.0001). Patients with CF/bronchiectasis also had a positive association (LR coefficient 2.48, p≤0.0001). Patients with cerebral palsy had a non-significant but positive coefficient (LR coefficient 0.65, p=0.302). In contrast, MND and OHS/OSA were negatively associated with the presence of Pa culture (LR coefficient −2.14, p=0.004, and −1.83, p=0.001, respectively).

| Patient group                         | Number of patients | Tracheostomy % | Pa positive n (%) |
|---------------------------------------|--------------------|----------------|------------------|
| Total patients                        | 837                | 147 (17.6)     |                  |
| Tracheostomy                          | 53                 | 38 (71.7)      |                  |
| Without tracheostomy                 | 784                | 109 (13.9)     |                  |
| 1. Respiratory conditions             |                    |                |                  |
| Tracheostomy                          | 256                | 0.0            | 59 (23.1)        |
| Without tracheostomy                 | 256                | 0.0            | 59 (23.1)        |
| a) Airway disease                     | 220                | 0.0            | 35 (15.9)        |
| b) CF and bronchiectasis             | 31                 | 0.0            | 23 (74.2)        |
| c) Interstitial lung diseases         | 5                  | 0.0            | 1 (20)           |
| 2. Restrictive chest wall conditions  |                    |                |                  |
| Tracheostomy                          | 54                 | 1.9            | 5 (9.3)          |
| Without tracheostomy                 | 53                 | 4 (7.4)        |                  |
| 3. Diaphragm palsy                    | 21                 | 4.8            | 1 (4.8)          |
| Tracheostomy                          | 1                  | 1 (100)        |                  |
| Without tracheostomy                 | 20                 | 0 (0)          |                  |
| 4. OHS and OSA                        | 162                | 0.0            | 6 (3.7)          |
| Tracheostomy                          | 0                  | 0 (0)          |                  |
| Without tracheostomy                 | 162                | 6 (3.7)        |                  |
| 5. Neuromuscular and neurological conditions |        |                |                  |
| Tracheostomy                          | 329                | 14.3           | 71 (21.6)        |
| Without tracheostomy                 | 47                 | 32 (68.1)      |                  |
| a) MND                                | 53                 | 9.4            | 3 (5.7)          |
| Tracheostomy                          | 5                  | 2 (40)         |                  |
| Without tracheostomy                 | 48                 | 1 (2.1)        |                  |
| b) DMD                                | 26                 | 15.4           | 7 (26.9)         |
| Tracheostomy                          | 4                  | 3 (75)         |                  |
| Without tracheostomy                 | 22                 | 4 (18.2)       |                  |
| c) All other neuromuscular disease    | 111                | 9.0            | 17 (15.3)        |
| Tracheostomy                          | 10                 | 8 (80)         |                  |
| Without tracheostomy                 | 101                | 9 (8.9)        |                  |
| d) Cerebral palsy                     | 19                 | 0.0            | 6 (31.6)         |
| Tracheostomy                          | 0                  | 0 (0)          |                  |
| Without tracheostomy                 | 19                 | 6 (31.6)       |                  |
| e) Spinal cord injury                 | 45                 | 33.3           | 18 (40)          |
| Tracheostomy                          | 15                 | 10 (66.7)      |                  |
| Without tracheostomy                 | 30                 | 8 (26.7)       |                  |
| f) Other neurological conditions      | 75                 | 17.3           | 20 (26.7)        |
| Tracheostomy                          | 13                 | 9 (69.2)       |                  |
| Without tracheostomy                 | 62                 | 11 (17.7)      |                  |
| 6. Other                              |                    |                |                  |
| Tracheostomy                          | 15                 | 26.7           | 5 (33.3)         |
| Without tracheostomy                 | 11                 | 1 (9.1)        |                  |

*Pa*: Pseudomonas aeruginosa; *CF*: cystic fibrosis; *OHS*: obesity hypoventilation syndrome; *OSA*: obstructive sleep apnoea; *MND*: motor neurone disease; *DMD*: Duchenne muscular dystrophy.
Isolates of copathogens

Commencement of a nebulised antibiotic had limited documentation, which hindered assessment of Pa suppression or effects on emerging pathogens. *Serratia*, *Proteus* species, *Stenotrophomonas*, *Burkholderia cepacia* complex and NTM were isolated in 8.5% of the LTV cohort and 33.3% of the Pa cohort. In the Pa cohort the copathogens cultured most frequently were *Serratia* (15.0%) and *Stenotrophomonas* (11.6%). Culture of copathogens was more frequent in patients colonised with Pa (OR 15.18, 95% CI 8.80–26.21, \(p \leq 0.0001\)) (see table 3).

| TABLE 3 Culture positive for copathogens |
|-----------------------------------------|
| Patient group                              | Number of patients| Pa positive n | Proportion of Pa with copathogen % |
|-------------------------------------------|------------------|----------------|-----------------------------------|
| *Serratia*, *Proteus* species, *Stenotrophomonas*, *Burkholderia cepacia* complex and NTM isolates | 71               | 49             | 33.3                              |
| Tracheostomy                              | 21               | 19             |                                   |
| Without tracheostomy                      | 50               | 30             |                                   |
| a) *Serratia* isolates                   | 31               | 22             | 15.0                              |
| Tracheostomy                              | 13               | 11             |                                   |
| Without tracheostomy                      | 18               | 11             |                                   |
| b) *Proteus* spp. isolates               | 17               | 12             | 8.2                               |
| Tracheostomy                              | 7                | 7              |                                   |
| Without tracheostomy                      | 10               | 5              |                                   |
| c) *Stenotrophomonas* isolates           | 21               | 17             | 11.6                              |
| Tracheostomy                              | 4                | 4              |                                   |
| Without tracheostomy                      | 17               | 13             |                                   |
| d) *Burkholderia cepacia* isolates       | 2                | 2              | 0.1                               |
| Tracheostomy                              | 0                | 0              | 0                                 |
| Without tracheostomy                      | 2                | 2              |                                   |
| e) NTM isolates                           | 6                | 5              | 3.4                               |
| Tracheostomy                              | 0                | 0              |                                   |
| Without tracheostomy                      | 6                | 5              |                                   |

*Pa*: *Pseudomonas aeruginosa*; NTM: nontuberculous mycobacteria.
The proportion of patients with one or more positive copathogen was highest in the patient groups CF/bronchiectasis (35.5%) and spinal cord injury (28.9%). Logistic regression to account for tracheostomy bias was not performed due to small sample size. However, there were no tracheostomy patients in the CF/bronchiectasis grouping but six in the spinal cord injury group.

52.7% of patients treated with a nebulised antibiotic grew copathogens.

**Management and treatment patterns**

In the *Pa* cohort 46.9% of patients received a long-term macrolide and 36.7% received a nebulised antibiotic. 21.1% patients received both a nebulised antibiotic and a long-term macrolide.

Azithromycin was prescribed in 18.5% of total patients and 46.9% of the *Pa* cohort. *Pa* colonisation was more common in patients prescribed azithromycin (OR 6.21, 95% CI 4.19–9.22, p≤0.0001).

36.7% of the *Pa* positive cohort were treated with a nebulised antibiotic. Colistin was the most frequently prescribed antibiotic (85.2%) (see figure 1).

In the tracheostomised *Pa* positive cohort, patients received a nebulised antibiotic more frequently (OR 2.63, 95% CI 1.23–5.64, p=0.013), and were colonised with a copathogen more often (OR 2.75, 95% CI 1.28–5.90, p=0.01) than *Pa* positive patients without a tracheostomy. Fewer patients in this group received azithromycin, but this difference was not significant (OR 0.61, 95% CI 0.28–1.30, p=0.202) (see table 4).

21.5% of all patients received LTOT and/or AOT, while in the *Pa* positive cohort 30.6% of patients received LTOT and/or AOT. *Pa* colonisation was more common in patients with LTOT and/or AOT (OR 1.84, 95% CI 1.23–2.73, p=0.003).

Carbocisteine was prescribed in 27.6% of total patients and 51.7% of the *Pa* positive cohort. *Pa* colonisation was more common in patients prescribed carbocisteine (OR 3.69, 95% CI 2.55–5.35, p<0.0001) (see table 5).

**Discussion**

*Pseudomonas aeruginosa* is a ubiquitous organism found in the natural environment but is frequently associated with both acute and chronic infections of the respiratory tract [6]. Recent paediatric research
suggested a 15% prevalence of *P. aeruginosa* in children with complex neuromuscular disorders and cerebral palsy [7]. The pathogen colonised 11% of a paediatric LTV cohort and reached a prevalence of 63% in LTV paediatric patients with a tracheostomy [7].

The current study is, to our knowledge, the first extensive work on *P. aeruginosa* isolates in an adult LTV cohort. Our key findings are that *P. aeruginosa* colonisation is frequent in adults on LTV, affecting nearly 1 in 5 (17.6%). Consistent with previous data [7], we found that tracheostomy is a significant factor influencing *P. aeruginosa* positive culture. Patients with CF and bronchiectasis also had high *P. aeruginosa* culture rates, an expected result as this pathogen is associated with these diseases. It is therefore expected to be intensified in a population with high disease severity requiring LTV [2]. Lastly, patients with a tracheostomy who were colonised with *P. aeruginosa* were more likely to receive treatment in the form of a nebulised antibiotic and have samples positive for copathogens (*Serratia*, *Proteus* species, *Stenotrophomonas*, *Burkholderia cepacia* complex and NTM).

The frequency of *P. aeruginosa* in the tracheostomy population was 71.7%, a higher rate than documented in previous paediatric studies [7]. Consistent with previous data [7], we also observed high rates of *P. aeruginosa* in the cohort with cerebral palsy, but these results were not significant. This likely reflects the small sample size in this group (19). Interestingly no patients with cerebral palsy had a tracheostomy.

Patients with OSA/OHS and MND were associated with a statistically significantly lower probability of culturing *P. aeruginosa* isolates. This outcome is not unexpected. LTV for OHS is associated with a reduced mortality (5-year survival 77.3%) than in untreated OHS [8]. High NIV adherence results in less hospital admission, and improved mortality [9]. We postulate that due to the rapid progression and reduced life expectancy in MND, the time period on LTV may be short, with lower lifetime antibiotic exposure and less time for acquisition of *P. aeruginosa*. Further research into the reduced frequency of *P. aeruginosa* in these disease categories is welcomed.

LTV services care for a diverse number of aetiologies. Since tracheostomy is associated with increased rates of *P. aeruginosa*, a useful tool for home ventilation clinicians is to understand which disease categories have higher rates of tracheostomy. We found patients with spinal cord injury had the highest prevalence of tracheostomy, followed by the groups “other” and DMD.

### TABLE 4 *P. aeruginosa* culture positive group

| *P. aeruginosa* culture | Number of patients | Treated n (%) | 95% CI | OR | 95% CI | p-value |
|-------------------------|--------------------|---------------|--------|----|--------|---------|
| Long-term macrolide: azithromycin |                    |               |        |    |        |         |
| Without tracheostomy    | 110                | 55 (50.0)     | 40.3–59.7 | 1   |         |         |
| Tracheostomy             | 37                 | 14 (37.8)     | 22.5–55.2 | 0.61| 0.28–1.30| 0.202   |
| Nebulised antibiotics    |                    |               |        |    |        |         |
| Without tracheostomy    | 110                | 34 (30.9)     | 22.5–40.4 | 1   |         |         |
| Tracheostomy             | 37                 | 20 (54.1)     | 36.9–70.5 | 2.63| 1.23–5.64| 0.013   |
| Culture positive for copathogen |                |               |        |    |        |         |
| Without tracheostomy    | 110                | 33 (30)       | 21.6–38.5 | 1   |         |         |
| Tracheostomy             | 37                 | 20 (54.1)     | 36.9–70.5 | 2.75| 1.28–5.90| 0.010   |

*P*: *Pseudomonas aeruginosa.*

### TABLE 5 Other management

| Other management                          | Number of patients (n) | *P. aeruginosa* positive n (%) | 95% CI | OR | 95% CI | p-value |
|-------------------------------------------|------------------------|--------------------------------|--------|----|--------|---------|
| No LTOT and/or AOT                        | 657                    | 101 (15.4)                     | 12.7–18.4 | 1  |         | 0.003   |
| LTOT and/or AOT                           | 180                    | 45 (25.0)                      | 17.9–30.5 | 1.84| 1.23–2.73| <0.0001 |
| No long-term macrolide: azithromycin      | 682                    | 78 (11.4)                      | 9.2–14.1 | 1  |         |         |
| Long-term macrolide: azithromycin         | 155                    | 69 (44.5)                      | 36.5–52.7 | 6.21| 4.19–9.22| <0.0001 |
| No mucolytic: carbocisteine               | 606                    | 71 (11.7)                      | 9.3–14.6 | 1  |         |         |
| Mucolytic: carbocisteine                  | 231                    | 76 (32.9)                      | 26.9–39.4 | 3.69| 2.55–5.35| <0.0001 |

*P*: *Pseudomonas aeruginosa*; LTOT: long-term oxygen therapy; AOT: ambulatory oxygen therapy.
Nearly half of *Pa* positive patients received treatment in the form of a long-term macrolide, and over a third received a nebulised antibiotic. Macrolide and nebulised antibiotic use are recommended in guidelines for preventing *Pa*-associated respiratory exacerbations for both bronchiectasis and CF. These agents are not specifically recommended in neuromuscular disease guidelines, and hence treatment is often empirical [10, 11]. There is a potential for these modalities to cause harm; colistin has been associated with respiratory arrest in myasthenia gravis [12] but also potential benefit, *i.e.* reducing/preventing *Pa* infections [12]. The clinical rationale for commencing antibiotic treatment in our cohort was not analysed, nor was exacerbation rate secondary to *Pa* infection, or the prevalence of *Pa*-associated pneumonia. A recent paediatric series [7] showed there was no immediate treatment benefit to acute anti-pseudomonals versus empirical antibiotics, highlighting the need for further research and understanding in this area.

There has been limited research regarding the prognostic significance of *Pa* in those with long-term tracheostomies [13, 14]. *Pa* has been shown to colonise tracheostomy tubes, forming biofilms [15]. Biofilms are recognised to cause an inherent resistance to antimicrobial treatment as well as bacterial persistence [7, 15]. Furthermore there is evidence of transmission to the lower airways resulting in complications such as pneumonia [16, 17]. As there are no clear guidelines for the management of *Pa* in long-term tracheostomy, treatment is guided by the patient’s clinical presentation and physicians’ acumen. In the acute ventilation setting there is a tendency to treat, reflecting the critical illness of these patients and the priority to prevent ventilator-associated pneumonia. We recorded a significant increase in treatment with a nebulised antibiotic in our *Pa* tracheostomy population (54.1%) but are unable to conclude whether this was guided by patients’ clinical deterioration/biochemical markers or solely triggered by the presence of tracheostomy. Another important variable to consider is sampling bias, and that tracheostomised patients may have sputums cultures sent more frequently as part of secretion management or for intentional surveillance.

There was a wide range in treatment modalities used in the management of these patients. This included combinations of and isolated use of long-term macrolides, nebulised colistin, nebulised aminoglycosides, cyclical nebulised antibiotic, *e.g.* tobramycin/colistin, and widespread use of carbocisteine as a mucolytic agent. It is important to recognise that prescription does not reflect adherence to treatment. Adherence to long-term nebulised antibiotic therapy can be challenging, and patients requiring LTV already have a significant treatment burden.

Within the *Pa* isolate cohort requirement for LTOT and/or AOT was not independent of diagnostic group. 80% of patients on LTOT and/or AOT had a respiratory diagnosis.

The exact date of commencement of a nebulised antibiotic had limited documentation, which hindered assessment of *Pa* suppression or effects on emerging pathogens. Similarly the COVID-19 pandemic has limited sputum sample collections as clinics carried out more remote consultations in 2020–2021. Within the cohort of *Pa* positive isolates, we had hoped to record the infective exacerbation rate pre- and post-treatment with *Pa* eradication antimicrobials. However, a key limitation to our study, reflecting the retrospective design, was the lack of documentation of this.

We found that *Serratia*, *Proteus* species, *Stenotrophomonas*, *Burkholderia cepacia* complex or NTM were isolated in 33.3% of the *Pa* cohort, and patients with a tracheostomy and *Pa* isolates were at increased risk of culturing a copathogen. This reflects the known association between tracheostomy and bacterial colonisation. A limitation to this research is we did not record the time period between isolating *Pa* and the copathogen. We recognise that the two isolates may have a significant time period between them. It is also possible the copathogen predates the first *Pa* isolate. NTM prevalence may be underestimated as growth requires rapid-growing mycobacteria medium to be specifically requested. The regional nature of the study resulted in samples being accessed across multiple sites and microbiology laboratories. These naturally will have slight variation in their approach to sample preparation.

An important question requiring further assessment is whether long-term antibiotics in LTV and LTV tracheostomy results in increased rates of virulent copathogens (*i.e.* multiple drug-resistant bacteria). Secondly, do long-term antimicrobials suppress *Pa* and/or exacerbation rates in this cohort? This is a point of major interest for the home ventilation community and also for antibiotic stewardship. It is important to balance treating infection against the potential future harm from antibiotic resistance.

The strengths of this study are the large sample size, data collection across multiple organisations and the description of treatment modalities applied. There are, however, limitations that need to be recognised, predominantly related to the retrospective design. Firstly, we cannot conclude that the prevalence described
here is truly representative – if a sample has not been requested as part of routine clinical assessment, we cannot confirm the absence of \( \text{Pa} \). Secondly, from the data gathered we do not know what proportion of \( \text{Pa} \) isolates represent asymptomatic colonisation versus a pathogen driving clinical deterioration. However, a degree of pragmatism is required when studying patients receiving LTV, acknowledging the reduced life expectancy seen in some subgroups which can make prospective study design challenging. Thirdly, although this was a regional study, we still encountered multiple aetiologies with small (n=1) cohorts (see supplementary material). This reflects the diversity of aetiologies managed by LTV services. In order to overcome this barrier a multicentre approach to data collection would be required. Additionally, we acknowledge that a valued piece of data would be the time period on LTV and/or tracheostomy to the first isolate of \( \text{Pa} \). Lastly, although infrequent, our service has patients who require home ventilation following a failed wean and level 3 intensive care. In the immediate period following discharge these patients may be colonised with hospital acquired bacteria. However, the mean number of days before the first episode of ventilator-associated pneumonia in home ventilation is 345 days suggesting a complex relationship between culture status and major infection episodes [5].

We conclude that \( \text{Pa} \) positive culture is common within the adult LTV population and is significantly associated with the presence of tracheostomy. This is an important consideration, adding to the high rates of healthcare burden already seen in this population [18] Patients managed with LTV, particularly those with a tracheostomy, should be considered for surveillance sputum culture as is already applied in other at-risk groups such as bronchiectasis. Research is required into whether \( \text{Pa} \) isolated in the adult LTV population drives morbidity and/or mortality, as seen in other diseases such as COPD and bronchiectasis [1, 2, 19]. This evidence will help formulate international guidelines on long-term antimicrobial management. Finally, when considering whether to proceed with tracheostomy in a LTV setting, the higher risk of \( \text{Pa} \) isolates and attendant treatment burden (i.e. limited oral or enteral antibiotic choices) should be discussed during multidisciplinary team meetings and shared decision making with the patient.

Provenance: Submitted article, peer reviewed.

Conflict of interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. B. Messer reports speakers’ fees from Fisher and Paykel outside the submitted work. A. De Soyza has received fees/grants from AstraZeneca, Bayer, GSK, Novartis, Grifols, Gilead and Zambon.

References

1 Chalmers J, Alberti S, Filonenko A, et al. Characterization of the “frequent exacerbator phenotype” in bronchiectasis. *Am J Respir Crit Care Med* 2018; 197: 1410–1420.
2 Finch S, McDonnell M, Abo-Leyah H, et al. A Comprehensive analysis of the impact of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis. *Ann Am Thorac Soc* 2015; 12: 1602–1611.
3 Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults. *Thorax* 2019; 74: Suppl. 1, 1–69.
4 Polverino E, Goeminne P, McDonnell M, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. *Eur Respir J* 2017; 50: 1700629.
5 Chenoweth C, Washler L, Obeyesekera K, et al. Ventilator-associated pneumonia in the home care setting. *Infect Control Hosp Epidemiol* 2007; 28: 910–915.
6 De Soyza A, Hall A, Mahenthiralingam E, et al. Developing an international *Pseudomonas aeruginosa* reference panel. *Microbiology/Open* 2013; 2: 1010–1023.
7 Gregson E, Thomas L, Elphick H. *Pseudomonas aeruginosa* infection in respiratory samples in children with neurodisability—treatment or not to treat? *Eur J Pediatr* 2021; 180: 2897–2905.
8 Priou P, Hamel JF, Person C, et al. Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. *Chest* 2010; 138: 84–90.
9 Masa JF, Benitez I, Sánchez-Quiroga MA, et al. Spanish Sleep Network. Long-term Noninvasive Ventilation in Obesity Hypoventilation Syndrome Without Severe OSA: The Pickwick Randomized Controlled Trial. *Chest* 2020; 158: 1176–1186.
10 Quinlivan R, Messer B, Murphy P, et al. Adult North Star Network (ANSN): Consensus Guideline For The Standard Of Care Of Adults With Duchenne Muscular Dystrophy. *J Neuromuscul Dis* 2021; 8: 899–926.
11 Hull J, Aniapravan R, Chan E, et al. British Thoracic Society guideline for respiratory management of children with neuromuscular weakness. *Thorax* 2012; 67: Suppl. 1, i1–i40.
12 Decker D, Fincham R. Respiratory arrest in myasthenia gravis with colistimethate therapy. *Arch Neurol* 1971; 25: 141–144.
13 Russell C, Simon T, Mamey M, et al. Pseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions. Pediatr Pulmonol 2017; 52: 1212–1218.
14 McCaleb R, Warren R, Willis D, et al. Description of respiratory microbiology of children with long-term tracheostomies. Respir Care 2015; 61: 447–452.
15 Donlan R, Costerton J. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167–193.
16 Raveendra N, Rathnakara S, Haswani N, et al. Bacterial biofilms on tracheostomy tubes. Indian J Otolaryngol Head Neck Surg 2021; in press [https://doi.org/10.1007/s12070-021-02598-6].
17 Sottile F, Marrie T, Prough D, et al. Nosocomial pulmonary infection. Crit Care Med 1986; 14: 265–270.
18 Windisch W. Impact of home mechanical ventilation on health-related quality of life. Eur Respir J 2008; 32: 1328–1336.
19 Eklöf J, Sørensen R, Ingebrigtsen T, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect 2020; 26: 227–234.